Francis Perier Jr. serves as Chief Financial Officer of the Company. Mr. Perier was retired following the 2014 acquisition of Forest Laboratories, Inc. by Actavis. From September 2004 to October 2014, Mr. Perier served as Chief Financial Officer of Forest Laboratories, Inc. Prior to Forest, Mr. Perier was with Bristol-Myers Squibb from 1995 to 2004, where he worked in corporate and operations executive finance capacities of increasing responsibilities, including Vice President of Finance and Operations Planning-Americas Medicines Group, the company’s largest business unit at that time. Before joining Bristol-Myers Squibb, Mr. Perier served as an accounting and auditing partner at Deloitte, where he worked for approximately 15 years. Mr. Perier also served as a member of the board of directors of Concordia International, Inc., a specialty pharmaceutical company from May 2017 until September 2018. Mr. Perier received an M.B.A. from the Stern School of Business, New York University and a Bachelor’s degree in Accountancy from Villanova University. He is a Certified Public Accountant (inactive) and a member of the New Jersey Society of Certified Public Accountants and the American Institute of Certified Public Accountants.
As the Chief Financial Officer of SpringWorks Therapeutics, the total compensation of Francis Perier at SpringWorks Therapeutics is $2,372,640. There are 1 executives at SpringWorks Therapeutics getting paid more, with Saqib Islam having the highest compensation of $3,284,920.
Francis Perier is 60, he's been the Chief Financial Officer of SpringWorks Therapeutics since 2019. There are 7 older and 12 younger executives at SpringWorks Therapeutics. The oldest executive at SpringWorks Therapeutics, Inc. is Freda Lewis-Hall, 65, who is the Independent Director.
Francis's mailing address filed with the SEC is C/O SPRINGWORKS THERAPEUTICS, INC., 100 WASHINGTON BLVD., STAMFORD, CT, 06902.
Over the last 6 years, insiders at SpringWorks Therapeutics have traded over $386,249,433 worth of SpringWorks Therapeutics stock and bought 800,000 units worth $14,400,000 . The most active insiders traders include Advisors Llc Orbi Med Capit..., Capital Life Sciences Inves... a Jeffrey Lawrence Schwartz. On average, SpringWorks Therapeutics executives and independent directors trade stock every 43 days with the average trade being worth of $6,795,384. The most recent stock trade was executed by Saqib Islam on 3 September 2024, trading 49,000 units of SWTX stock currently worth $1,987,930.
SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas, as well as Phase 1/2a clinical trial for the treatment of NF1-PN; mirdametinib + lifirafenib, a combination therapy that is in Phase 1b/2 clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat solid tumors. In addition, it develops BGB-3245, an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations, which is in Phase I clinical trial. The company has collaborations with BeiGene, Ltd., GlaxoSmithKline LLC, and Allogene to develop combination approaches with nirogacestat and mirdametinib; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. In addition, the company has clinical collaboration agreement with Janssen Biotech, Inc., Precision BioSciences, Inc., Seagen Inc., and AbbVie, Inc. SpringWorks Therapeutics, Inc. was founded in 2017 and is headquartered in Stamford, Connecticut.
SpringWorks Therapeutics executives and other stock owners filed with the SEC include: